Clinician Scientist
Dr. med. Philipp Makowka
Department of medicine, Hematology/Oncology
Research Focus: Patient-specific/individualized/pre-therapeutic prediction of therapy sensitivities
Contact: makowka@med.uni-frankfurt.de
Member of the Serve Lab
Acute myeloid leukemia (AML) is characterized by pronounced heterogeneity and diverse resistance mechanisms, making the prediction of therapy response particularly challenging. BH3 profiling enables functional analysis of apoptosis regulation and provides insights into sensitivities to specific drugs. Using the flow cytometry–based variant (iBH3 profiling), Dr. Philipp Makowka applies this method directly to viable cells from fresh bone marrow. The aim is to establish it as a diagnostic routine tool within the context of the molecular tumor board to support more patient-centered therapy decisions and to enable the testing of novel therapeutics in an ex vivo setting.
Find out more about the Serve Lab here.
